Wed, 4 November 2015
Are there Clinically Significant Differences Among Immune Checkpoint Inhibitors Treating Lung Cancer?
Drs. Leora Horn, Ben Solomon, & Jack West consider whether the data suggest that the better tested PD1 and PD-L1 inhibitors have differences in activity or tolerability or are essentially interchangeable.
Direct download: GRACEcast-388_WCLC_2015_Clinically_Significant_Differences_Immune_Checkpoint_Inhibitors.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT